Navigation Links
Rigel Announces Second Quarter 2013 Financial Results
Date:8/6/2013

rd-looking" statements, including, without limitation, statements related to the further development of certain drug candidates, including to the future plans with respect to fostamatanib and the timing of announcement of those plans and the results of certain studies, and the sufficiency of our funds and the timing of our cash.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "expect," and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Rigel's product candidates and our need for additional capital in the future to sufficiently fund our operations and research, the uncertain timing of completion of and the success of clinical trials and the potential problems that may arise in the clinical development process, and that our corporate collaborations or license agreements may be unsuccessful, market competition, risks associated with and Rigel's dependence on Rigel's corporate partnerships, as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the three months ended March 31, 2013. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

 

Contact: Ryan D. Maynard
Phone: 650.624.1284'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Rigel Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015 ... is essential to meeting challenges in clinical development, market ... face tighter regulations, the Medical Affairs function is expected ... by mature markets. According to research ... study participants have a group dedicated to Medical Affairs. ...
(Date:3/27/2015)... 2015 Object recognition technology has a unique ... elderly. The VelaSense ® mobile platform ... independent, productive and fulfilling lives. VelaSense ® will ... to identify objects from a one million object database, ... object databases for personal use. Visus ...
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
... 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and Adolor ... and,provided an update on the clinical development ... 3, double blind, placebo-controlled (12,month) study, was ... of alvimopan 0.5 mg twice daily in ...
Cached Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:3/28/2015)... MILAN (PRWEB) March 28, 2015 ... thought-leaders in the fields of osteoporosis, osteoarthritis and ... on Osteoporosis, it may be the first time ... educational research forum that the hot-button topic is ... Based on the well-accepted scientific principles of Wolff’s ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... 24 Many religions teach that selflessly "doing unto ... , , A growing body of ... promoting health and general well-being--research that will be outlined more fully ... Research Says." (1) , , ...
... fertility solutions,agencies today announced the launch of a unique cooperative ... donors dropping out before the,retrieval process is completed. , ... is an initiative by The Center for Egg,Options (CEO), Northbrook, ... Egg donation is an ...
... institution , ... Washington, DC (Vocus) November 24, 2008 ... , dedicated new research facilities today, increasing the space of one ... square feet. , , , , ,Elected officials and scientific leaders ...
... For over a decade Ochsner Health System,has enjoyed ... in improved patient care, cost savings and increased revenues ... of New Orleans have,seen more than their share of ... have left the greater New Orleans hospital infrastructure,badly damaged. ...
... its January 1,2009 opening, San Francisco Village-Northside (SFV-N) announces ... (IOA). , SFV-N ... older adults and those who care for them live ... they wish or are,able. A model that is sweeping ...
... think of the holidays,as a time for joy and togetherness. ... emotionally trying time. The buildup of the,pressure to create the ... negative consequences, such as depression,anxiety and substance dependency. , ... ) , "During the ...
Cached Medicine News:Health News:Conferees to Explore How Religious Practice Reaps Health 2Health News:Conferees to Explore How Religious Practice Reaps Health 3Health News:Three Chicago Area Fertility Agencies Launch 'Shared Risk' Program 2Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News:Under Wraps: Uncovering the Secrets and Lies of the Holiday Season 2
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... The S8 Elite is the premium CPAP device ... generators. The S8 line of flow generators are ... first flow generators to include an option of ... to the device for simplicity and convenience. Premium ...
Medicine Products: